Supplementary materials for: The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials

Table I. Trial Registration Table II: Efficacy Outcomes Scales Table III: Proportion of Patients Achieving EASI 75 During Treatment in the Escape Arm Table IV. Overview of Adverse Events Table V. Rescue Therapy Usage from Week 16 to Week 52 Figure 1. Study Design for ADvocate1 and ADvocate2 Figure 2. ADvocate1 and ADvocate2 Pooled Patient Disposition Figure 3. Time Course of Response (Supportive Analysis)表I. 试验注册信息 表II. 疗效结局量表 表III. 逃逸组治疗期间达到EASI 75的患者比例 表IV. 不良事件概况 表V. 第16周至第52周的解救治疗使用情况 图1. ADvocate1与ADvocate2试验研究设计方案 图2. ADvocate1与ADvocate2试验合并患者转归汇总 图3. 应答时间进程（支持性分析）